Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma

Experimental Hematology & Oncology

Frédéric Peyrade¹  Antoine Thyss¹  Jean Gutnecht²  Richard Skaf⁵  Salvatore Caruso⁴  Annick Boscagli¹  Mario Ojeda-Uribe³  Lauris Gastaud¹  Magalie P. Tardy¹ 

[1] Department of Oncology, Antoine-Lacassagne Center, Nice, France;Department of Oncology, Frejus-Saint Raphael Hospital, Frejus, France;Department of Hematology, Mulhouse Hospital, Mulhouse, France;La Dracenie Hospital Center, Draguignan, France;Department of Oncology, Saint-Georges Clinic, Nice, France

关键词: Z-BeEAM;    Conditionning regimen;    Autologous stem cell transplantation;    Large B cell lymphoma;    Aggressive Non-Hodgkin lymphoma;   

Others  :  1220361
DOI  :  10.1186/s40164-015-0013-2

 received in 2015-05-26, accepted in 2015-06-23,  发布年份 2015

【 摘 要 】

Background

Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently carmustine availability became difficult. The purpose of this study was to evaluate the feasibility and the safety of replacing carmustine by bendamustine in a new Z-BeEAM regimen (ibritumomab tiuxetan, bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation.

Findings

This study was a retrospective analyze of six patients, with a median age of 60, treated by Z-BeEAMbefore autologous stem cell transplantation. We did not put in evidence any additional toxicities compared to conventional induction chemotherapy. The main toxicities were mucositis (3 grade III among 6 patients), gastrointestinal (2 grade III vomiting and 2 grade III diarrhea) and neutropenia (6 grade IV). Engraftment was successfully achieved for all patients. At the time of analysis of this study all patients were alive and in complete response based on the PET-CT evaluation.

Conclusions

BeEAM plus ibritumomab tiuxetan combined regimen before autologous stem cell transplantation is feasible and safe in aggressive relapsing large B-cell lymphoma.

【 授权许可】

   
2015 Tardy et al.

【 参考文献 】

• [1]Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al.. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 2010; 28:4184-90.
• [2]Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al.. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1995; 333:1540-5.
• [3]Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin’s lymphoma. Ann. Oncol. 1998; 9 Suppl 1:S15-21.
• [4]Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C et al.. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Biol. Blood Marrow Transplant. 2014; 20:1905-11.
• [5]Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R et al.. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012; 118:4706-14.
• [6]Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al.. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011; 118:3419-25.
• [7]Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al.. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: the Lugano Classification. J. Clin. Oncol. 2014; 32:3059-67.
• [8]Fernandez HF, Escalón MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant. 2007; 40:505-13.
• [9]Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J. Clin. Oncol. 1995; 13:588-95.
• [10]Martin N, Borchiellini D, Coso D, Gastaud L, Boscagli A, Saudes L, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk. Lymphoma 1–9 (2015). Epub ahead of print. doi:10.3109/10428194.2014.1001987
• [11]Auger-Quittet S, Duny Y, Daures J-P, Quittet P. Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med. 2014; 3:927-38.
• [12]Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C et al.. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin. Lymphoma Myeloma Leuk. 2010; 10:258-61.
• [13]Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al.. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72 % 3-year PFS in resistant lymphoma. Blood. 2014; 124:3029-31.